title: Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants.
abstract: BACKGROUND
  Prematurity and the associated risk for bronchopulmonary dysplasia (BPD) remain a significant threat to extremely low birth weight (ELBW) infants. Vitamin A has been considered a therapeutic alternative in reducing the rate of BPD and mortality.
  
  
  OBJECTIVE
  To investigate whether early postnatal, additional high-dose oral vitamin A supplementation for 28 days is more efficient in reducing BPD or death in ELBW infants than placebo treatment.
  
  
  METHODS
  This is a multicenter, double-blind RCT comparing postnatal high-dose oral vitamin A supplementation (5,000 IU vitamin A/kg/day vs. placebo) for 28 days in ELBW neonates requiring mechanical ventilation, noninvasive ventilatory support or supplemental oxygen at 24 h of age. The primary end point is the proportion of children who died before 36 weeks' gestational age or developed moderate or severe BPD. BPD is defined as the need for supplemental oxygen to maintain SaO2 of ≥92% at rest at 36 weeks' postmenstrual age (PMA). Clinical secondary end points include the following: BPD (including mild form), intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, total number of days of mechanical ventilation and oxygen supplementation, and safety and tolerability of high-dose vitamin A supplementation.
  
  
  CONCLUSIONS
  The results of the NeoVitaA trial will provide robust data with regard to the efficacy of high-dose oral vitamin A supplementation in reducing the incidence of BPD or death at 36 weeks' PMA in ELBW infants.
authors.affiliation: Neonatal Intensive Care Unit, Department of Pediatrics and Neonatology, University Children's Hospital of Saarland, Homburg, Germany.
authors.forename: Sascha
authors.initials: S
authors.lastname: Meyer
authors.forename: Ludwig
authors.initials: L
authors.lastname: Gortner
mesh_terms: D000284:Administration, Oral; D001724:Birth Weight; D001997:Bronchopulmonary Dysplasia / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005858:Germany; D006801:Humans; D007223:Infant; D007226:Infant Mortality; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects* / Q000254:growth & development / Q000503:physiopathology; D063087:Noninvasive Ventilation / Q000009:adverse effects; D010102:Oxygen Inhalation Therapy / Q000009:adverse effects; D011446:Prospective Studies; D012107:Research Design; D012121:Respiration, Artificial / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D014801:Vitamin A / Q000008:administration & dosage*
chemical_list: D014801:Vitamin A